Table 2.

Risk of COVID-19 in the IBD Evusheld cohort compared to IBD control cohort and non-IBD control before and after propensity score matching.

CohortN (%)Before propensity score matchingN (%)After propensity score matching
aOR (95% CI)aOR (95% CI)
IBD Evusheld55 (13.4%)2.57 (1.93-3.42)51 (13%)1.35 (0.87–2.10)
IBD Control3793 (5.7%)39 (10%)
IBD Evusheld55 (13.4%)1.36 (1.01-1.82)52 (12.9%)1.02 (0.67–1.54)
Non-IBD control1021 (10.2%)51 (12.7%)
CohortN (%)Before propensity score matchingN (%)After propensity score matching
aOR (95% CI)aOR (95% CI)
IBD Evusheld55 (13.4%)2.57 (1.93-3.42)51 (13%)1.35 (0.87–2.10)
IBD Control3793 (5.7%)39 (10%)
IBD Evusheld55 (13.4%)1.36 (1.01-1.82)52 (12.9%)1.02 (0.67–1.54)
Non-IBD control1021 (10.2%)51 (12.7%)

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; IBD, inflammatory bowel disease.

Table 2.

Risk of COVID-19 in the IBD Evusheld cohort compared to IBD control cohort and non-IBD control before and after propensity score matching.

CohortN (%)Before propensity score matchingN (%)After propensity score matching
aOR (95% CI)aOR (95% CI)
IBD Evusheld55 (13.4%)2.57 (1.93-3.42)51 (13%)1.35 (0.87–2.10)
IBD Control3793 (5.7%)39 (10%)
IBD Evusheld55 (13.4%)1.36 (1.01-1.82)52 (12.9%)1.02 (0.67–1.54)
Non-IBD control1021 (10.2%)51 (12.7%)
CohortN (%)Before propensity score matchingN (%)After propensity score matching
aOR (95% CI)aOR (95% CI)
IBD Evusheld55 (13.4%)2.57 (1.93-3.42)51 (13%)1.35 (0.87–2.10)
IBD Control3793 (5.7%)39 (10%)
IBD Evusheld55 (13.4%)1.36 (1.01-1.82)52 (12.9%)1.02 (0.67–1.54)
Non-IBD control1021 (10.2%)51 (12.7%)

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; IBD, inflammatory bowel disease.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close